[HTML][HTML] Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint …
EJ Lipson, VE Velculescu, TS Pritchard… - … for immunotherapy of …, 2014 - Springer
Background Assessment of therapeutic activity of drugs blocking immune checkpoints such
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
[HTML][HTML] Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint …
EJ Lipson, VE Velculescu… - Journal for …, 2014 - jitc.biomedcentral.com
Assessment of therapeutic activity of drugs blocking immune checkpoints such as CTLA-4
and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear anew before …
and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear anew before …
[HTML][HTML] Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint …
EJ Lipson, VE Velculescu, TS Pritchard… - … for Immunotherapy of …, 2014 - ncbi.nlm.nih.gov
Background Assessment of therapeutic activity of drugs blocking immune checkpoints such
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
EJ Lipson, VE Velculescu, TS Pritchard… - … for ImmunoTherapy of …, 2014 - go.gale.com
Background Our group and others have previously reported that circulating tumor DNA
(ctDNA) can be detected in the plasma of patients with advanced melanoma and other …
(ctDNA) can be detected in the plasma of patients with advanced melanoma and other …
[HTML][HTML] Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint …
EJ Lipson, VE Velculescu, TS Pritchard… - … for ImmunoTherapy of …, 2014 - jitc.bmj.com
Background Assessment of therapeutic activity of drugs blocking immune checkpoints such
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
[PDF][PDF] Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint …
EJ Lipson, VE Velculescu, TS Pritchard, M Sausen… - 2014 - core.ac.uk
Background: Assessment of therapeutic activity of drugs blocking immune checkpoints such
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.
EJ Lipson, VE Velculescu, TS Pritchard… - … for Immunotherapy of …, 2014 - europepmc.org
Background Assessment of therapeutic activity of drugs blocking immune checkpoints such
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
EJ Lipson, VE Velculescu… - Journal for …, 2014 - pure.johnshopkins.edu
Background: Assessment of therapeutic activity of drugs blocking immune checkpoints such
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
[PDF][PDF] Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint …
EJ Lipson, VE Velculescu, TS Pritchard, M Sausen… - 2014 - scienceopen.com
Background: Assessment of therapeutic activity of drugs blocking immune checkpoints such
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
EJ Lipson, VE Velculescu… - Journal for …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Assessment of therapeutic activity of drugs blocking immune checkpoints such
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …